SAM
PTCT icon

Shell Asset Management’s PTC Therapeutics PTCT Stock Holding History

Shell Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$28K Sell
451
-700
-61% -$36.5K ﹤0.01% 990
2025
Q2 		$56K Sell
1,151
-120
-9% -$5.7K ﹤0.01% 1128
2025
Q1 		$65K Sell
1,271
-52
-4% -$2.6K ﹤0.01% 1099
2024
Q4 		$60K Hold
1,323
– – ﹤0.01% 1150
2024
Q3 		$49K Buy
+1,323
New +$44.3K ﹤0.01% 1184
2024
Q1 		$43K Sell
1,401
-81
-5% -$2.27K ﹤0.01% 1178
2023
Q4 		$41K Sell
1,482
-445
-23% -$10.2K ﹤0.01% 1198
2023
Q3 		$43K Sell
1,927
-29
-1% -$1.08K ﹤0.01% 1207
2023
Q2 		$80K Sell
1,956
-11
-0.6% -$538 ﹤0.01% 1158
2023
Q1 		$95K Sell
1,967
-7
-0.4% -$320 ﹤0.01% 1116
2022
Q4 		$75K Sell
1,974
-331
-14% -$13.8K ﹤0.01% 1222
2022
Q3 		$116K Sell
2,305
-620
-21% -$30.4K ﹤0.01% 1180
2022
Q2 		$117K Buy
2,925
+1,362
+87% +$47.8K ﹤0.01% 1249
2022
Q1 		$58K Sell
1,563
-236
-13% -$9.09K ﹤0.01% 1336
2021
Q4 		$72K Sell
1,799
-29
-2% -$1.11K ﹤0.01% 1349
2021
Q3 		$68K Sell
1,828
-70
-4% -$2.88K ﹤0.01% 1345
2021
Q2 		$80K Hold
1,898
– – ﹤0.01% 1397
2021
Q1 		$90K Sell
1,898
-3,304
-64% -$196K ﹤0.01% 1306
2020
Q4 		$317K Hold
5,202
– – 0.01% 980
2020
Q3 		$243K Hold
5,202
– – 0.01% 980
2020
Q2 		$264K Sell
5,202
-80
-2% -$3.93K 0.01% 946
2020
Q1 		$236K Sell
5,282
-80
-1% -$4.03K 0.01% 960
2019
Q4 		$258K Sell
5,362
-138
-3% -$5.86K 0.01% 1086
2019
Q3 		$186K Sell
5,500
-47
-0.8% -$2.05K ﹤0.01% 1141
2019
Q2 		$250K Buy
+5,547
New +$219K 0.01% 1080

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shell Asset Management's PTCT Position: Q3 2025 in Review

Shell Asset Management reduced its PTC Therapeutics (PTCT) stake by 61% in Q3 2025, selling an estimated $36.5K and leaving 451 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #990.

Shell Asset Management first reported a position in PTCT in Q2 2019 and has held it in 25 quarters since. The position peaked at $317K in Q4 2020. 294 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Shell Asset Management held 451 shares of PTC Therapeutics worth $28K as of Q3 2025.
  • Shell Asset Management sold 700 PTC Therapeutics shares in Q3 2025, an estimated $36.5K.
  • PTC Therapeutics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #990 holding.
  • Shell Asset Management first reported a position in PTC Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Shell Asset Management's PTC Therapeutics position peaked at $317K in Q4 2020.
  • 294 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.